Durvalumab: all 557 studies that test it
Page 4 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2
- Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2
- An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2
- Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
- Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or ChemoradiotherapyStatus unknownNCT05267392Phase 1/2
- Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II StudyStatus unknownNCT05262985Phase 2
- Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Active, not recruitingNCT05215106Phase 2
- Chemo-free BRCA-targeted Neoadjuvant StrategyWithdrawnNCT05209529Phase 2
- Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)Active, not recruitingNCT05206812Phase 2
- Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT TrialWithdrawnNCT05161533Phase 2
- Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLCStatus unknownNCT05157542Phase 1
- Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedNCT05154994Phase 1
- A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive, not recruitingNCT05137262Phase 2
- Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLCActive, not recruitingNCT05092412Phase 2
- TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
- Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung CancerStatus unknownNCT05034133Phase 2
- Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyActive, not recruitingNCT05000710Phase 2
- TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular CarcinomaActive, not recruitingNCT04988945Phase 2
- To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.Active, not recruitingNCT04985851Not applicable
- A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLCStatus unknownNCT04982549Phase 2
- Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3
- SCION: SABR and Checkpoint Inhibition of NSCLCWithdrawnNCT04944173Phase 2
- Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerActive, not recruitingNCT04940286Phase 2
- SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular CarcinomaStatus unknownNCT04913480Phase 2
- A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerCompletedNCT04905316Phase 2
- Lung Cancer With Copanlisib and DurvalumabCompletedNCT04895579Phase 1
- Vactosertib and Durvalumab in Gastric CancerStatus unknownNCT04893252Phase 2
- Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain MetastasesWithdrawnNCT04889066Phase 2
- Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell CarcinomaStatus unknownNCT04851132Not applicable
- TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 2
- The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersActive, not recruitingNCT04781192Phase 1/2
- Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCTerminatedNCT04765709Phase 2
- Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With DurvalumabTerminatedNCT04748419Phase 1/2
- Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialActive, not recruitingNCT04728230Phase 1/2
- Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation TherapyActive, not recruitingNCT04716946Phase 2
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesActive, not recruitingNCT04711824Phase 1/2
- Combining Epigenetic And Immune Therapy to Beat Cancer.CompletedNCT04705818Phase 2
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04699838Phase 2
- The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid TumorsTerminatedNCT04696848Phase 1/2
- Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingNCT04668300Phase 2
- Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics ModelsStatus unknownNCT04646837Phase 1/2
- Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentWithdrawnNCT04625699Phase 2
- A Study of MEDI9253 in Combination With Durvalumab in Select Solid TumorsTerminatedNCT04613492Phase 1
- Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT04607954Phase 2
- Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerActive, not recruitingNCT04605731Phase 1
- A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial CarcinomaStatus unknownNCT04603846Phase 1
- Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)Active, not recruitingNCT04602533Phase 2
- Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction CancerActive, not recruitingNCT04592913Phase 3
- Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)SuspendedNCT04585477Phase 2
- Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04568200Phase 2
- Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCActive, not recruitingNCT04550260Phase 3
- Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBCStatus unknownNCT04543110Phase 2
- First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
- Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Active, not recruitingNCT04472949Phase 2
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaActive, not recruitingNCT04462328Phase 1
- A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.Status unknownNCT04460066Phase 1/2
- Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04447612Phase 2
- Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicable
- Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04397003Phase 2
- Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological MalignanciesActive, not recruitingNCT04395079Phase 2
- Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyActive, not recruitingNCT04392505Phase 2
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsCompletedNCT04361825Phase 2
- Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04356222Phase 4
- DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2
- Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionCompletedNCT04294498Phase 2
- Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal CancerStatus unknownNCT04293419Phase 2
- Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentTerminatedNCT04287894Phase 1
- A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2
- A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTIONWithdrawnNCT04262375Phase 2
- IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.CompletedNCT04261075Phase 1
- Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompletedNCT04257448Phase 1/2
- Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04255836Phase 2
- Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04245514Phase 2
- Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerWithdrawnNCT04231864Phase 2
- Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study GroupActive, not recruitingNCT04230759Phase 2
- Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersCompletedNCT04230408Phase 2
- Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid CarcinomaCompletedNCT04224337Phase 2
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1
- Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT04221555Phase 2
- A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE TrialActive, not recruitingNCT04216290Phase 2
- Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
- Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingNCT04169841Phase 2
- Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic CancerCompletedNCT04156087Phase 2
- Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRCWithdrawnNCT04145193Phase 2
- Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCCCompletedNCT04124991Phase 1/2
- CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)Active, not recruitingNCT04116047Phase 3
- Diadem to Investigate the Activity and Safety of DurvalumabCompletedNCT04115111Phase 2
- Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal CancerTerminatedNCT04108481Phase 1
- Immunotherapy in Patient With Poor General ConditionCompletedNCT04108026Phase 2
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
- Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1
- TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder CancerWithdrawnNCT04073160Phase 1
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2
- Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04054518Phase 2
- Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2
- Tri Association in Patient With Advanced Epithelial Ovarian Cancer in RelapseStatus unknownNCT04015739Phase 2
- Therapy for High-Risk HPV 16-Positive Oropharynx Cancer PatientsWithdrawnNCT04001413Phase 2